Antibody responses to Yersinia pestis F1-antigen expressed in Salmonella typhimurium aroA from in vivo-inducible promoters

Bullifent, Helen L.; Griffin, Kate F.; Jones, Steven M.; Yates, Amanda; Harrington, L.; Titball, Richard W.

doi:10.1016/s0264-410x(00)00053-0

Cited by 32 publications

(27 citation statements)

References 33 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Salmonella vaccine vectors are adept for delivering vaccines and mimicking natural infections of the gut (21). These recombinant Salmonella vaccines can target mucosal inductive tissues (PP) and ultimately disseminate and stimulate both mucosal and systemic arms of the immune system (29,30).…”

Section: Discussionmentioning

confidence: 99%

“…In pV3 plasmid, V-Ag was regulated by tetracycline promoter (PtetA) (20), in which the tetracycline structure gene was deleted. In pV4 plasmid, V-Ag was regulated by a macrophage inducible promoter from S. Typhimurium H683 phoP gene (PphoP) (21). In pV55 plasmid, V-Ag was regulated by the fusion PtetA and PphoP promoters.…”

Section: Construction Of Caf1 Operon and V-ag To A Balanced-lethal Stmentioning

confidence: 99%

“…To ensure that our Salmonella vaccine could induce elevated anti-V-Ag Ab titers, we tested two promoters and their chimera to determine the degree to which the V-Ag expression can be enhanced. Henceforth, the plasmids pV3, pV4, and pV55, in which lcrV are respectively regulated by PtetA (20), PphoP (21), and a chimeric promoter of PtetA and PphoP were constructed.…”

Section: Oral Immunization With Salmonella-v-ag Constructs Elicits Vamentioning

confidence: 99%

See 2 more Smart Citations

Oral Vaccination withSalmonellaSimultaneously ExpressingYersinia pestisF1 and V Antigens Protects against Bubonic and Pneumonic Plague

Yang

Hinnebusch

Trunkle

et al. 2007

The Journal of Immunology

View full text Add to dashboard Cite

The gut provides a large area for immunization enabling the development of mucosal and systemic Ab responses. To test whether the protective Ags to Yersinia pestis can be orally delivered, the Y. pestis caf1 operon, encoding the F1-Ag and virulence Ag (V-Ag) were cloned into attenuated Salmonella vaccine vectors. F1-Ag expression was controlled under a promoter from the caf1 operon; two different promoters (P), PtetA in pV3, PphoP in pV4, as well as a chimera of the two in pV55 were tested. F1-Ag was amply expressed; the chimera in the pV55 showed the best V-Ag expression. Oral immunization with Salmonella-F1 elicited elevated secretory (S)-IgA and serum IgG titers, and Salmonella-V-Ag(pV55) elicited much greater S-IgA and serum IgG Ab titers than Salmonella-V-Ag(pV3) or Salmonella-V-Ag(pV4). Hence, a new Salmonella vaccine, Salmonella-(F1+V)Ags, made with a single plasmid containing the caf1 operon and the chimeric promoter for V-Ag allowed the simultaneous expression of F1 capsule and V-Ag. Salmonella-(F1+V)Ags elicited elevated Ab titers similar to their monotypic derivatives. For bubonic plague, mice dosed with Salmonella-(F1+V)Ags and Salmonella-F1-Ag showed similar efficacy (>83% survival) against ∼1000 LD50 Y. pestis. For pneumonic plague, immunized mice required immunity to both F1- and V-Ags because the mice vaccinated with Salmonella-(F1+V)Ags protected against 100 LD50 Y. pestis. These results show that a single Salmonella vaccine can deliver both F1- and V-Ags to effect both systemic and mucosal immune protection against Y. pestis.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Construction Of Caf1 Operon and V-ag To A Balanced-lethal Stmentioning

confidence: 99%

Section: Oral Immunization With Salmonella-v-ag Constructs Elicits Vamentioning

confidence: 99%

See 1 more Smart Citation

Oral Vaccination withSalmonellaSimultaneously ExpressingYersinia pestisF1 and V Antigens Protects against Bubonic and Pneumonic Plague

Yang

Hinnebusch

Trunkle

et al. 2007

The Journal of Immunology

View full text Add to dashboard Cite

show abstract

“…In the past decade, the use of attenuated bacterial pathogens such as Listeria monocytogenes, Shigella flexneri and a variety of attenuated Salmonella serovars have proven useful in the generation of both antibody and cell-mediated protective immunity in animal infection or tumor models [1][2][3]. In most cases, constitutive expression of heterologous protein antigens by these bacterial carriers in vivo elicits protective immune responses [4][5][6]. In addition to this strategy, Salmonella typhimurium and Shigella flexneri have been used to deliver plasmid DNA vaccines to elicit protective immune responses in mice [2,7].…”

Section: Introductionmentioning

confidence: 99%

Immunization with non-replicating E. coli minicells delivering both protein antigen and DNA protects mice from lethal challenge with lymphocytic choriomeningitis virus

Giacalone

Zapata

Berkley

et al. 2007

Vaccine

View full text Add to dashboard Cite

In the midst of new investigations into the mechanisms of both delivery and protection of new vaccines and vaccine carriers, it has become clear that immunization with delivery mechanisms that do not involve living, replicating organisms are vastly preferred. In this report, non-replicating bacterial minicells simultaneously co-delivering the nucleoprotein (NP) of lymphocytic choriomeningitis virus (LCMV) and the corresponding DNA vaccine were tested for the ability to generate protective cellular immune responses in mice. It was found that good protection (89%) was achieved after intramuscular administration, moderate protection (31%) was achieved after intranasal administration, and less protection (7%) was achieved following gastric immunization. These results provide a solid foundation on which to pursue the use of bacterial minicells as a non-replicating vaccine delivery platform.

show abstract

“…Generally, these vectors tend to bias host immunity along T helper type 1 (Th1)-cell-dependent pathways because of their invasive properties or intracellular requirement. Yet we (34,35) and others (7,19) have shown that Salmonella vectors can convert Th1-type biases to Th2-type biases by mode of passenger antigen expression (1,34). It has been established that the extracellular secretion of enterotoxigenic Escherichia coli fimbrial adhesin colonization factor antigen I (CFA/I) produces a biphasic Th cell response supporting enhanced production of secretory immunoglobulin A (S-IgA) antibodies (Abs) (34).…”

mentioning

confidence: 99%

Enhanced Immunoglobulin A Response and Protection againstSalmonella entericaSerovar Typhimurium in the Absence of the Substance P Receptor

et al. 2005

View full text Add to dashboard Cite

The development of the neurokinin-1 receptor-deficient (NK1R−/−) mouse permitted inquiry into the regulation of secretory immunoglobulin A (S-IgA) responses by substance P (SP) after oral immunization with a Salmonella enterica serovar Typhimurium vector expressing colonization factor antigen I (CFA/I) from enterotoxigenic Escherichia coli. In NK1R−/− mice, mucosal and serum IgA anti-CFA/I fimbrial responses were augmented, while secreted IgG anti-CFA/I fimbrial responses remained unaffected compared to those of BALB/c (NK1R+/+) mice. Supportive antibody-forming cells were present in the small intestinal lamina propria and spleen. To gain insight as to why the augmented S-IgA responses occurred, minimally, the responses were not attributed to differences in vaccine colonization of Peyer's patch (PP) and spleen or in their respective tissue weights. However, these S-IgA responses were supported by increased numbers of PP CD4+ T helper (Th) cells secreting interleukin-5 (IL-5) and IL-6 and splenic CD4+ Th cells secreting IL-6 compared to NK1R+/+ mice. Challenge of naive NK1R−/− mice with wild-type Salmonella showed improved median survival compared to naive NK1R+/+ mice. Data from peritoneal macrophage infection studies suggest that this survival is in part contributed by increased IL-10 production. Oral vaccination with Salmonella CFA/I or Salmonella vector showed no significant differences in conferred protection against wild-type challenge for either NK1R−/− or NK1R+/+ mice. Thus, these studies suggest that SP mediation contributes to proinflammatory responses to Salmonella infections

show abstract

Antibody responses to Yersinia pestis F1-antigen expressed in Salmonella typhimurium aroA from in vivo-inducible promoters

Cited by 32 publications

References 33 publications

Oral Vaccination withSalmonellaSimultaneously ExpressingYersinia pestisF1 and V Antigens Protects against Bubonic and Pneumonic Plague

Oral Vaccination withSalmonellaSimultaneously ExpressingYersinia pestisF1 and V Antigens Protects against Bubonic and Pneumonic Plague

Immunization with non-replicating E. coli minicells delivering both protein antigen and DNA protects mice from lethal challenge with lymphocytic choriomeningitis virus

Enhanced Immunoglobulin A Response and Protection againstSalmonella entericaSerovar Typhimurium in the Absence of the Substance P Receptor

Contact Info

Product

Resources

About